Skip to content

S. 1844 · 118th Congress (2023–2025)

Animal Drug and Animal Generic Drug User Fee Amendments of 2023

This bill reauthorizes the Food and Drug Administration (FDA) to collect fees for brand-name and generic animal drug applications through FY2028. It also makes related updates to fee calculations and FDA reporting requirements.

The bill also (1) provides for a specific fee for requests to establish generic investigational new animal drug files and requires other application fees to be adjusted accordingly; (2) authorizes the FDA to remove species from the definition of major species (currently horses, dogs, cats, cattle, pigs, chickens, and turkeys); (3) provides statutory authority for the FDA to report on its progress supporting antimicrobial stewardship in veterinary settings (i.e., supporting responsible use of antimicrobial drugs for animals to slow the development of drug-resistant bacteria); and (4) provides for the regulation of zootechnical animal food substances as food additives (zootechnical animal food substances are added to the food or drinking water of animals to affect the byproducts of the animal's digestion, reduce foodborne pathogens, or alter the animal's gastrointestinal biome).

Animal drugs are drugs that are intended for animals other than humans (e.g., pets and livestock). Animal drugs must be approved by the FDA before they may be offered on the commercial market. The FDA is authorized to collect fees for animal drug applications in order to support its regulatory activities; this authority currently expires at the end of FY2023.

Show official title

A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize user fee programs relating to new animal drugs and generic new animal drugs.

Expired in Senate committee

Derived from the legislative history, not an official disposition.

Latest actionReported by committee

This bill’s path

This is S. 1844’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Sen. Tammy Baldwin (D-WI)
Cosponsors
1 cosponsor

1 original · 0 later

  1. Sen. Markwayne Mullin (R-OK)· Original · Jun 7, 2023
Policy area
Health
Subjects
  • Research and development
  • User charges and fees
  • Veterinary medicine and animal diseases

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest
    ▸ 3 committee actions · Jun 7, 2023 – Jul 26, 2023
    1. Referred to committee

      Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

      Sources
    2. Ordered reported

      Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment favorably.

      Sources
    3. Reported by committee

      Committee on Health, Education, Labor, and Pensions. Reported by Senator Sanders with an amendment. Without written report.

      Sources
  3. Expired

    Introduced → Reported by committee → No further action before the 118th Congress ended.

Committees

  1. SenateHealth, Education, Labor, and PensionsReferred Jun 7, 2023 · Markup Jun 15, 2023 · Reported Jul 26, 2023
    1. Jun 15, 2023 · Meeting

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Reported to Senate
Titles (4)
  1. Animal Drug and Animal Generic Drug User Fee Amendments of 2023

    Display title, Short title · Introduced in Senate, Reported to Senate

  2. Animal Generic Drug User Fee Amendments of 2023

    Short title · Introduced in Senate, Reported to Senate · portion of the bill

  3. Animal Drug User Fee Amendments of 2023

    Short title · Introduced in Senate, Reported to Senate · portion of the bill

  4. A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize user fee programs relating to new animal drugs and generic new animal drugs.

    Official title · Introduced in Senate